(Q36746701)

16 August 2017

1 reference

title

The treatment of acute myeloid leukaemia preceded by the myelodysplastic syndrome (English)

1 reference

16 August 2017

1 reference

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

11 November 2022

author name string

T. Hamblin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1732662

11 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1732662

11 November 2022

publication date

1 January 1992

1 reference

full work available at URL

16 August 2017

https://api.elsevier.com/content/article/PII:014521269290108J?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

https://api.elsevier.com/content/article/PII:014521269290108J?httpAccept=text/plain

11 November 2022

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

11 November 2022

1 reference

16 August 2017

volume

16

1 reference

16 August 2017

issue

1

1 reference

16 August 2017

page(s)

101-108

1 reference

Postleukemic dysmyelopoiesis

16 August 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Myelodysplastic relapse of de novo acute myeloid leukaemia with trilineage myelodysplasia: a previously unrecognized correlation

11 November 2022

3

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

True outlook in acute myeloblastic leukaemia

11 November 2022

5

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasia

11 November 2022

6

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphocytic leukemia

11 November 2022

7

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Multiple chromosomally distinct cell populations in myelodysplastic syndromes and their possible significance in the evolution of the disease

11 November 2022

8

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Remission of acute myelogenous leukemia in elderly patients with prior refractory dysmyelopoietic anemia

11 November 2022

9

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial

11 November 2022

11

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia

11 November 2022

12

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome

11 November 2022

13

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes

11 November 2022

16

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study.

11 November 2022

17

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Aggressive chemotherapy in adult primary myelodysplastic syndromes. A report on 29 cases

11 November 2022

19

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Intensive chemotherapy for acute non-lymphoblastic leukemia after primary myelodysplastic syndrome

11 November 2022

20

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes

11 November 2022

21

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Post-therapeutic acute leukemia

11 November 2022

22

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Short-term treatment for acute myelogenous leukaemia

11 November 2022

29

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly

11 November 2022

30

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Treatment of acute nonlymphocytic leukemia in young and elderly patients.

11 November 2022

31

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial

11 November 2022

32

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group

11 November 2022

33

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Intensive treatment of acute leukemia in adults 70 years of age and older

11 November 2022

34

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Treatment of acute myeloid leukemia in elderly patients. A retrospective study.

11 November 2022

35

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Treatment of acute myeloid leukemia in the elderly: a clinical dilemma

11 November 2022

37

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group

11 November 2022

38

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Acute myeloid leukemia in elderly adults.

11 November 2022

40

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly

11 November 2022

41

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Expression of the multidrug resistance gene in myeloid leukemias.

11 November 2022

43

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy

11 November 2022

44

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Remission maintenance therapy in acute myelogenous leukemia

11 November 2022

45

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival

11 November 2022

48

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG)

11 November 2022

49

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome

11 November 2022

50

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Response of preleukemic syndromes to continuous infusion of low-dose cytarabine

11 November 2022

52

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Therapeutic effects of low-dose cytosine arabinoside, alpha-interferon, 1 alpha-hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes

11 November 2022

55

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

Hematologic response of four patients with smoldering acute myelogenous leukemia to partially pure gamma interferon

11 November 2022

56

1 reference

https://api.crossref.org/works/10.1016/0145-2126(92)90108-J

11 November 2022

Identifiers

1 reference

16 August 2017

1 reference